Premium
Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients a randomized trial
Author(s) -
Viladiu Pablo,
Alonso Maria Carmen,
Avella Antonio,
Beltrán Miguel,
Borrás Juan,
Ojeda Belen,
Bosch F. Xavier
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19851215)56:12<2745::aid-cncr2820561204>3.0.co;2-g
Subject(s) - medicine , cyclophosphamide , chemotherapy , vincristine , tamoxifen , breast cancer , randomized controlled trial , medroxyprogesterone acetate , oncology , methotrexate , fluorouracil , cancer , doxorubicin , gynecology , surgery , estrogen
One hundred seventeen postmenopausal advanced breast cancer patients previously untreated with chemotherapy were randomized to receive: (A) cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF), (B) CMF and tamoxifen (TMX), and (C) CMF and medroxyprogesterone (MAP). Treatments B and C induced a greater proportion of responses than treatment A. No effect was identified on the number of complete responses. After treatment failure, patients from groups A and C received Adriamycin (doxorubicin) (ADX) vincristine (VCR), and TMX and patients from group B received ADM, VCR, and MAP. No differences were found between the branches in the response rates to the second protocol. Responders to both treatments had a longer survival experience than nonresponders or responders to only one of the treatments. Survival was independent of the treatment group.